Solid Tumors, Adult Clinical Trial
Official title:
A Single-arm Phase I Clinical Study of TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors
This is a multicenter, single-arm phase I clinical trial.The study process was divided into: screening period, sampling and production period, clear lung pretreatment period, treatment and observation period, and follow-up period.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04467853 -
A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT05698888 -
Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04587479 -
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT05472220 -
Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma
|
Phase 1 | |
| Recruiting |
NCT05354323 -
NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05430373 -
GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04739293 -
Study of ON 123300 in Patients With Advanced Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT05747339 -
A Clinical Study on the Efficacy and Mechanism of Tumor Treatment Vaccine (TTV) for Recurrent and Refractory Advanced Solid Tumors
|
N/A | |
| Recruiting |
NCT05887492 -
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05228015 -
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT05018273 -
Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04621435 -
Imaging of Solid Tumors Using FAP-2286
|
Phase 1 | |
| Recruiting |
NCT05861895 -
A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05768139 -
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 |